Allogene Therapeutics, Inc.
ALLO- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001737287
In the last 90 days, Allogene Therapeutics, Inc. insiders filed 0 open-market purchases and 1 sale; 209 institutions reported holding it in 13F filings for Q2 2026, worth $652.0M in total; no superinvestor holds it.
13F holders, Q4 2022
Institutional positions in Allogene Therapeutics, Inc. as of Dec 31, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 168
- −21 vs. Q3 2022
- Shares held
- 111.5M
- +5.48M (+5.2%) vs. Q3 2022
- Total value
- $700.9M
- −$443.4M (−38.7%) vs. Q3 2022
- New holders
- 20
- 67 more added
- Sold out
- 41
- 55 more reduced
3 institutions that held it in Q3 2022 haven't filed for Q4 2022 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q3 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ALLO on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 209 | $652.0M |
| Q1 2026 | 209 | $444.7M |
| Q4 2025 | 172 | $222.7M |
| Q3 2025 | 170 | $201.0M |
| Q2 2025 | 158 | $207.9M |
| Q1 2025 | 171 | $288.5M |
| Q4 2024 | 174 | $401.9M |
| Q3 2024 | 156 | $460.4M |
| Q2 2024 | 175 | $385.1M |
| Q1 2024 | 161 | $586.0M |
| Q4 2023 | 170 | $392.4M |
| Q3 2023 | 155 | $413.3M |
| Q2 2023 | 171 | $662.9M |
| Q1 2023 | 176 | $582.3M |
| Q4 2022 | 168 | $700.9M |
| Q3 2022 | 192 | $1.15B |
| Q2 2022 | 161 | $1.15B |
| Q1 2022 | 180 | $836.7M |
| Q4 2021 | 177 | $1.28B |
| Q3 2021 | 169 | $2.26B |
| Q2 2021 | 182 | $2.25B |
| Q1 2021 | 169 | $3.12B |
Institutions, Q4 2022
Shares, value and share of portfolio for each institution holding Allogene Therapeutics, Inc.; share changes are against Q3 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Marshall Wace, LLP | 0 | $0 | 0.00% | −12,593−100.0% | Sold out |
| Bailard, Inc. | 0 | $0 | 0.00% | −11,600−100.0% | Sold out |
| Oppenheimer & Co Inc | 0 | $0 | 0.00% | −11,350−100.0% | Sold out |
| DuPont Capital Management Corp | 0 | $0 | 0.00% | −11,365−100.0% | Sold out |
| Leonteq Securities AG | 0 | $0 | 0.00% | −7,500−100.0% | Sold out |
| Simplex Trading, LLC | 0 | $0 | 0.00% | −2,050−100.0% | Sold out |
| Jackson, Grant Investment Advisers, Inc. | 0 | $0 | 0.00% | −469−100.0% | Sold out |
| Allworth Financial LP | 0 | $0 | 0.00% | −37−100.0% | Sold out |
| Evoke Wealth, LLC | 0 | $0 | 0.00% | −32−100.0% | Sold out |
| Eaton Vance Management | – | – | – | – | Not filed |
| Shikiar Asset Management Inc | – | – | – | – | Not filed |
| Wipfli Financial Advisors LLC, | – | – | – | – | Not filed |